CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for听multiple myeloma.听
Highlights
The global CAR T-Cell Therapy for Multiple Myeloma market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The increasing number of collaborations or licensing agreements between companies and research institute, will induce the involvement of more investors in this area. Car T-cell therapy for multiple myeloma has identified that most of the pipeline molecules in multiple myeloma are currently in the pre-clinical development stage. KMA.CAR-T the drug is under development by the company HaemaLogiX. This monotherapy drug is currently in the pre-clinical stage and the company has already signed an agreement with Westmead Institute for Medical Research.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CAR T-Cell Therapy for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR T-Cell Therapy for Multiple Myeloma.
The CAR T-Cell Therapy for Multiple Myeloma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global CAR T-Cell Therapy for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR T-Cell Therapy for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Juno Therapeutics
Kite Pharma
Novartis
Collectis
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Multiple Myeloma
Refractory or Relapsed Multiple Myeloma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR T-Cell Therapy for Multiple Myeloma companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Monotherapy
1.2.3 Combination Therapy
1.3 麻豆原创 by Application
1.3.1 Global CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Multiple Myeloma
1.3.3 Refractory or Relapsed Multiple Myeloma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Perspective (2018-2029)
2.2 CAR T-Cell Therapy for Multiple Myeloma Growth Trends by Region
2.2.1 Global CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 CAR T-Cell Therapy for Multiple Myeloma Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 CAR T-Cell Therapy for Multiple Myeloma Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Dynamics
2.3.1 CAR T-Cell Therapy for Multiple Myeloma Industry Trends
2.3.2 CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Drivers
2.3.3 CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Challenges
2.3.4 CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR T-Cell Therapy for Multiple Myeloma Players by Revenue
3.1.1 Global Top CAR T-Cell Therapy for Multiple Myeloma Players by Revenue (2018-2023)
3.1.2 Global CAR T-Cell Therapy for Multiple Myeloma Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CAR T-Cell Therapy for Multiple Myeloma Revenue
3.4 Global CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Concentration Ratio
3.4.1 Global CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR T-Cell Therapy for Multiple Myeloma Revenue in 2022
3.5 CAR T-Cell Therapy for Multiple Myeloma Key Players Head office and Area Served
3.6 Key Players CAR T-Cell Therapy for Multiple Myeloma Product Solution and Service
3.7 Date of Enter into CAR T-Cell Therapy for Multiple Myeloma 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR T-Cell Therapy for Multiple Myeloma Breakdown Data by Type
4.1 Global CAR T-Cell Therapy for Multiple Myeloma Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global CAR T-Cell Therapy for Multiple Myeloma Forecasted 麻豆原创 Size by Type (2024-2029)
5 CAR T-Cell Therapy for Multiple Myeloma Breakdown Data by Application
5.1 Global CAR T-Cell Therapy for Multiple Myeloma Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global CAR T-Cell Therapy for Multiple Myeloma Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size (2018-2029)
6.2 North America CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Country (2018-2023)
6.4 North America CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size (2018-2029)
7.2 Europe CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Country (2018-2023)
7.4 Europe CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size (2018-2029)
9.2 Latin America CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Country (2018-2023)
9.4 Latin America CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Juno Therapeutics
11.1.1 Juno Therapeutics Company Detail
11.1.2 Juno Therapeutics Business Overview
11.1.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Introduction
11.1.4 Juno Therapeutics Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2018-2023)
11.1.5 Juno Therapeutics Recent Development
11.2 Kite Pharma
11.2.1 Kite Pharma Company Detail
11.2.2 Kite Pharma Business Overview
11.2.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Introduction
11.2.4 Kite Pharma Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2018-2023)
11.2.5 Kite Pharma Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Introduction
11.3.4 Novartis Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Collectis
11.4.1 Collectis Company Detail
11.4.2 Collectis Business Overview
11.4.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Introduction
11.4.4 Collectis Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2018-2023)
11.4.5 Collectis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Juno Therapeutics
Kite Pharma
Novartis
Collectis
听
听
*If Applicable.
